Biogen Inc. Furnishes Second Quarter 2026 Financial Results
Summary
Biogen Inc. (Nasdaq: BIIB) announced its second quarter 2026 financial results on July 29, 2026, via a press release (Ex. 99.1). The company reported total revenue of $2.7 billion, a 3% increase year-over-year. Its Growth Portfolio generated $1.06 billion in revenue, growing 24% year-over-year. GAAP diluted EPS was $0.66, and Non-GAAP diluted EPS was $3.60. These results reflect progress in repositioning the company for long-term growth.
Why It Matters
Investors should note Biogen's reported 3% year-over-year total revenue growth to $2.7 billion and 24% growth in its Growth Portfolio revenue to $1.06 billion, as detailed in Ex. 99.1. These figures, along with GAAP diluted EPS of $0.66 and Non-GAAP diluted EPS of $3.60, signal the company's progress in its strategic repositioning for sustainable revenue growth.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how BIIB traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View BIIB Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000875045
- Filing Date
- Wednesday, July 29, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive